Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$8.9B
119M shares
52-week range
$51.06 – $82.22
88% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
www.halozyme.comNo one on the platform currently holds HALO.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 731,811 | $47.3M |
| Bridgewater Associatesas of 2026-03-31 | 511,429 | $33.1M |
No one on the platform has traded HALO yet.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$HALO alerts at 71.5, 74.5 and 78.5. Would like to see price tighten up before highs.
View on StockTwits ↗$HALO https://www.cnbc.com/video/2026/06/29/final-trade-halo-baba-googl-spcx.html
View on StockTwits ↗$HALO On June 26, 2026, Jim Cramer and Jeff Marks of the https://www.cnbc.com/investingclub/morning-meeting/ specifically highlighted Halozyme Therapeutics, pointing to its extended product revenue runway.
View on StockTwits ↗Or they go Thursday 🐑 in da $FATE of da YO then out of the tightness da $HALO protects YO ENTA 🐒🍌🧠⏰♾️
View on StockTwits ↗$HALO FROM AI - PTAB Rulings: A Major Victory for Halozyme (June 29) The U.S. Patent Trial and Appeal Board (PTAB) issued a significant ruling.The Decision: The Board rejected Merck's arguments and upheld Halozyme’s challenged claims, ruling that Merck failed to prove they were "obvious".The Takeaway: The PTAB concluded that modifying the specific molecular structures in question would have required "undue experimentation" by prior art standards. This is a massive defensive win for Halozyme, preserving its core patent fortress as the broader District Court case moves forward in New Jersey.
View on StockTwits ↗$GILD $HALO $ANIP $MRK gild added 125.8...the current basket, also holding ELAN ARWR
View on StockTwits ↗$HALO ok looks like you are now ready! Just had to be patient!!!
View on StockTwits ↗Have no fear the $HALO is here to protect YO. Now let’s get $NUTX ONTO 🐒🍌🧠⏰♾️
View on StockTwits ↗@cynicaloptimist @BustaCapital @Jblack500 @MaverikIT @IsabellaDC @WAJeff take your medicine while tech cools off $MRK $ARWR $HALO $ANIP $GILD
View on StockTwits ↗$MA in MA. Added more this week. If you like toll booth economics, check out $HALO
View on StockTwits ↗@WAJeff @MaverikIT @BustaCapital @No_Face_character @cynicaloptimist @IsabellaDC been choppy since I bought it but $HALO trying
View on StockTwits ↗$HALO Not a big bang deal, however, can appreciate building shareholder value 1 brick at a time. "LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care and specialty care today announced a strategic co-marketing collaboration supporting a direct-to-patient self-pay program for XYOSTED® (testosterone enanthate)." https://ir.lifemd.com/press-release-details.php?newsId=3315216
View on StockTwits ↗$HALO @JR603 it is likely overstating what thE UK court actually said on this link: https://caselaw.nationalarchives.gov.uk/ewhc/pat/2026/1287 1. Halozyme consented to revocation of the UK designation of EP 2797622 (EP 622). 2. Merck sought something more: a summary judgment that Halozyme’s infringement claim had “no real prospect of success.” 3. Judge Hacon refused. 4. The judge expressly acknowledged Halozyme’s concern that Merck might use such language in Germany and stated: “I cannot dismiss the possibility” that Merck intended to invite the German court to draw an inference extending further than appropriate. 5. The judge held that the infringement counterclaim was dismissed simply because EP 622 was being revoked in the UK, and he saw “no reason for summary judgment.” “Halozyme consents to revocation of UK EP 622; court refuses to grant Merck broader merits judgment.” Continued pursuit of EP 3 130 347 in the UK (according to Halozyme’s German appeal brief).
View on StockTwits ↗$HALO Seoul Economic Daily Alteogen Partner MSD Wins UK Patent Suit Against Halozyme Favorable Result Also Emerges in US 'Keytruda SC' Uncertainty Resolved UGH !!!!!
View on StockTwits ↗$ARWR $HALO arwr new 52 week nice to see..halo backtested breakout of channel
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.